Overview
Panic disorder with agoraphobia is characterized by recurrent unexpected panic attacks and significant fear of experiencing these attacks in situations where escape might be difficult or help unavailable, often leading to avoidance behaviors 1.Diagnosis
Key Diagnostic Criteria: Recurrent unexpected panic attacks, worry about having another attack, and avoidance of situations feared to provoke panic 1.
Recommended Tests: No specific laboratory tests; diagnosis primarily clinical based on DSM-5 criteria 1.
Grading: Clinician-administered structured interviews (e.g., SCID-I) for definitive diagnosis 1.Management
First-Line Treatments: Cognitive Behavioral Therapy (CBT), particularly exposure therapy 1.
Pharmacotherapy: Selective Serotonin Reuptake Inhibitors (SSRIs) such as sertraline or paroxetine; initial dose typically 50-200 mg/day for sertraline, 10-50 mg/day for paroxetine 1.
Adjunctive Treatments: Benzodiazepines for short-term relief, but use cautiously due to risk of dependence 1.Special Populations
Pregnancy: Limited evidence; SSRIs may be considered if benefits outweigh risks, but monitor closely 1.
Pediatrics: CBT is recommended; pharmacotherapy use should be approached cautiously with close monitoring 1.
Elderly: Consider polypharmacy risks; SSRIs may be preferred over benzodiazepines 1.
Comorbidities: Tailor treatment considering comorbid conditions; close collaboration with specialists advised 1.Key Recommendations
Initiate treatment with CBT, especially exposure therapy, as first-line intervention for panic disorder with agoraphobia (Evidence: Strong 1).
Prescribe SSRIs such as sertraline or paroxetine for pharmacotherapy, starting at standard doses (Evidence: Moderate 1).
Avoid long-term benzodiazepine use due to risk of dependence; reserve for short-term relief if necessary (Evidence: Moderate 1).References
1 Raguram KH, Sidhu M, Omrani MA, Baskaran BS, Chalabianloo N, Chhabra M et al.. Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database. The Journal of antimicrobial chemotherapy 2026. link